Childhood Hodgkins Survivor Scales Everest

Sean Swarner, a survivor of Hodgkin's lymphoma at age 13 and also Askin's sarcoma a year later, has scaled several mountains including recently Mount Everest. He is setting his sights on becoming only the fifth person in history to accomplish the so-called "adventure grand slam." This involves climbing to the top of the tallest mountain on each of the earth's seven continents and trekking to both the north and south poles.



"Most of the outfitters told me that there's no way they'd take a one lung, two-time cancer survivor lunatic up the highest mountain in the world," he said. On Everest, he faced 100 mph winds, snowstorms, deadly avalanches, and a significant loss of oxygen -- hazards that challenge even the most accomplished climbers. "And the sherpas were kind of scared too because in Nepal there's no such thing as a cancer survivor," he said.



But for Swarner, taking on Everest was a lot like fighting cancer. "Everyone has their own Everest to climb. And everyone is battling their own mountains and fighting cancer and going through the treatments is an uphill struggle," he said.



Swarner is the only known cancer survivor to have reached the summit of Mount Everest.



You can read more about Sean here.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap